REGENERON PHARMACEUTICALS's ticker is REGN and the CUSIP is 75886F107. A total of 478 filers reported holding REGENERON PHARMACEUTICALS in Q3 2014. The put-call ratio across all filers is 1.54 and the average weighting 0.3%.
About REGENERON PHARMACEUTICALS
Regeneron Pharmaceuticals is a biotechnology company that specializes in the development of innovative medicines for the treatment of serious diseases. The company has a strong pipeline of products that are in various stages of development, including treatments for cancer, eye diseases, and inflammatory conditions.
One of the most promising products in Regeneron's pipeline is Dupixent, a treatment for atopic dermatitis, which is a chronic skin condition that affects millions of people worldwide. Dupixent has already been approved by the FDA and is expected to generate significant revenue for the company in the coming years.
Regeneron has also been working on a treatment for COVID-19, which has been in high demand since the outbreak of the pandemic. The company's treatment, called REGN-COV2, has shown promising results in clinical trials and has been granted emergency use authorization by the FDA.
In addition to its strong pipeline of products, Regeneron has a solid financial position, with a market capitalization of over $60 billion. The company has a strong track record of delivering value to its shareholders, with a five-year total return of over 200%.
Overall, Regeneron Pharmaceuticals is a company with a bright future. Its innovative products and strong financial position make it an attractive investment opportunity for those looking to invest in the biotechnology sector.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $510,406,000 | +67.3% | 1,317,162 | +58.5% | 0.42% | +62.3% |
| Q4 2016 | $305,063,000 | -6.8% | 831,043 | +2.0% | 0.26% | -6.9% |
| Q3 2016 | $327,484,000 | +0.5% | 814,858 | -12.7% | 0.28% | -0.4% |
| Q2 2016 | $325,962,000 | -43.1% | 933,400 | -41.2% | 0.28% | -44.3% |
| Q1 2016 | $572,646,000 | -45.6% | 1,588,630 | -18.1% | 0.50% | -44.6% |
| Q4 2015 | $1,052,793,000 | -47.4% | 1,939,345 | -54.9% | 0.90% | -0.2% |
| Q3 2015 | $2,000,156,000 | +97.1% | 4,300,074 | +116.1% | 0.90% | +7.8% |
| Q2 2015 | $1,014,807,000 | +36.8% | 1,989,448 | +21.1% | 0.83% | +36.7% |
| Q1 2015 | $741,577,000 | +713.7% | 1,642,443 | +639.4% | 0.61% | +682.1% |
| Q4 2014 | $91,134,000 | +29.3% | 222,144 | +13.6% | 0.08% | +21.9% |
| Q3 2014 | $70,496,000 | +47.5% | 195,539 | +15.6% | 0.06% | +45.5% |
| Q2 2014 | $47,797,000 | -6.9% | 169,210 | -1.0% | 0.04% | -8.3% |
| Q1 2014 | $51,328,000 | -9.8% | 170,936 | -17.3% | 0.05% | -11.1% |
| Q4 2013 | $56,894,000 | -31.7% | 206,706 | -22.4% | 0.05% | -34.9% |
| Q3 2013 | $83,288,000 | -2.3% | 266,206 | -29.8% | 0.08% | -6.7% |
| Q2 2013 | $85,219,000 | – | 378,951 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tekla Capital Management LLC | 211,166 | $63,409,000 | 6.34% |
| Signpost Capital Advisors, LP | 43,326 | $13,010,000 | 5.52% |
| Rhenman & Partners Asset Management AB | 55,792 | $16,753,000 | 5.03% |
| SECTORAL ASSET MANAGEMENT INC | 307,400 | $92,306,000 | 3.80% |
| RAY GERALD L & ASSOCIATES LTD | 67,870 | $20,380,000 | 3.69% |
| BB BIOTECH AG | 223,000 | $66,962,000 | 3.45% |
| PINNACLE ASSOCIATES LTD | 545,601 | $163,833,000 | 3.20% |
| Sands Capital Management | 4,012,062 | $1,204,742,000 | 3.14% |
| DSM CAPITAL PARTNERS LLC | 483,267 | $145,116,000 | 3.03% |
| MAGEE THOMSON INVESTMENT PARTNERS LLC | 40,810 | $12,254,000 | 2.78% |